Journal ArticleOPEN ACCESS

Brolucizumab for wet age‐related macular degeneration

  • Chaplin S
Prescriber (2020) 31(9) 33-35
DOI: 10.1002/psb.1867
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Brolucizumab (Beovu) is a new monoclonal antibody fragment targeting VEGF‐A for the treatment of neovascular (wet) age‐related macular degeneration (AMD). This article outlines its mechanism of action, place in therapy, clinical efficacy and adverse effects.

Cite

CITATION STYLE

APA

Chaplin, S. (2020). Brolucizumab for wet age‐related macular degeneration. Prescriber, 31(9), 33–35. https://doi.org/10.1002/psb.1867

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free